跳至主要内容
临床试验/NCT01648686
NCT01648686已完成不适用

Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os (70 mg Weekly)

Assistance Publique - Hôpitaux de Paris2 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2012年9月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
66
试验地点
2
主要终点
Alveolar socket filled by new bone

研究概览

简要总结

The purpose of this study is to determine whether the oral alendronate treatment of post-menopausal osteoporosis could be a risk factor for jaw bone healing after dental extraction.

详细描述

Alendronate is the main oral bisphosphonate used in the treatment and the prevention of the postmenopausal osteoporosis because of its high antiresorbant ability for bone tissue. Alendronate delayed bone healing after dental extraction on animals models, murine as canine. Anti-angiogenic and anti-osteoclastic characteristics are suggested to explain this phenomenon. There is no available data in human and it is now well known that bisphosphonates are involved in the occurrence of osteonecrosis of the jaws even if this major adverse effect seems to be very seldom with oral alendronate. Moreover, bisphosphonate showed toxicity for oral mucosal cells. The main aim of this study is to quantify the impact of oral alendronate weekly treatment on bone and mucosa healing after dental extraction in postmenopausal osteoporotic women. A secondary aim is to investigate a panel of 50 peptids potentially involved in bone and mucosal healing and to detect changes in their rates by salivary proteomic approach. The investigators hope so identify salivary biomarkers of bone and/or mucosa healing in these women.

Our hypothesis is that after dental extraction, bone healing could be delayed in postmenopausal osteoporotic women treated with oral weekly alendronate (BP+ group) versus matched osteoporotic women untreated with bisphosphonates (BP- group).

This is a prospective and multicentric (17 investigation centers dispatched in France) study including 140 osteoporotic postmenopausal women treated weekly with oral bisphosphonates (BP+ group) and 140 osteoporotic postmenopausal women untreated with bisphosphonates (BP- group). This is a clinical follow-up study (T0, T0 + 7, T0 + 30, T0 + 90 days), a radiological study (T0, T0 + 30, T0 + 90 days), and a salivary proteomic study (T0, T0 + 30, T0 + 90 days). This is a 4 years study starting in april 2012 (anticipated date).

The main investigated parameters are:

  • Bone healing: Bone filling rate (in %) of the post-extractional alveolar socket (BFR) at T0, T0 + 30 and T0 + 90 days by a radiographic approach.
  • Mucosa healing: mucosal injury by metric approach at T0 and T0 + 30 days.
  • Salivary biomarkers: Fifty peptides by proteomic approach at T0 and T0 + 30 days;

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Screening
盲法
None

入排标准

年龄范围
45 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Postmenopausal osteoporotic women
  • Treated with alendronate per os (70 pg weekly) for BP+ experimental group and untreated with this therapy for the BP
  • Control group
  • Subjected to single root tooth extraction- 45 to 70 years of age

排除标准

  • Maxillofacial irradiations
  • Dental extraction with adjunction of material interfering with bone healing
  • Severe pathologies inconsistent with this study
  • Bisphosphonate treatment for BP- control group
  • Women treated with denosumab (prolia®)
  • Women already included to an another dental extraction

结局指标

主要结局

Alveolar socket filled by new bone

时间窗: 3 months after extraction

Rate in % of the alveolar socket filled by new bone

次要结局

  • Mucosal injury(7 days after extraction)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验